Second-line chemotherapy of epithelial ovarian cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 1, 2003, Pages 31-36

  Markman, Maurie ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Altretamine; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Liposomal doxorubicin; Neurotoxicity; Ovarian cancer; Paclitaxel; Topotecan

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LIPOSOME; NAVELBINE; PACLITAXEL; PLATINUM; TAMOXIFEN; TOPOTECAN;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL TRIAL; DRUG ACTIVITY; DRUG COST; DRUG FORMULATION; DRUG PREFERENCE; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; REVIEW; TREATMENT PLANNING; VOMITING;

EID: 0037320736     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.1.31     Document Type: Review

References (42)

1. Kottmeier HL. Treatment of ovarian cancer with thiotepa. Clin. Obstet. Gynecol. 11, 428-4438 (1968).
2. Thigpen T, Vance R, Lambuth B et al. Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 60, 2104-2116 (1987).
3. Cannistra SA. Cancer of the ovary. N. Engl. J. Med. 329, 1550-1559 (1993).
4. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334, 1-6 (1996).
5. Piccart MJ, Bertelsen K, James K et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl Cancer Inst. 92, 699-708 (2000).
6. Ozols RF, Bundy BN, Fowler J et al. Randomized Phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158). Proc. Am. Soc. Clin. Oncol. 18, 356a (1999).
7. du Bois A, Richter B, Warm M et al. Cisplatin/paclitaxel versus carboplatin/paclitaxel as 1st-line treatment in ovarian cancer. Proc. Am. Soc. Clin. Oncol. 17, 361a (1998).
8. Vasey PA. Survival and longer-term toxicity results of the SCOTROC study: docetaxel-carboplatin (DC) versus paclitaxel-carboplatin (PC) in epithelial ovarian cancer (EOC). Proc. Am. Soc. Clin. Oncol. 21, 202a (2002).
9. Vasey PA. Preliminary results of the SCOTROC trial: a Phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC). Proc. Am. Soc. Clin. Oncol. 20, 202a (2001).
10. Markman M, Liu PY, Wilczynski S, Monk BJ, Copeland L, Alberts D. Phase III randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy. A Southwest Oncology Group and Gynecologic Oncology Group trial. Gynecol. Oncol. 84, 479 (2002).
11. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens. Gynecol. Oncol. 65, 434-436 (1997).
12. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389-393 (1991).
13. Gershenson DM, Kavanagh JJ, Copeland LJ, Stringer CA, Morris M, Wharton JT. Retreatment of patients with recurrent epithelial ovarian cancer with cisplatin-based chemotherapy. Obstet. Gynecol. 73, 798-802 (1989).
14. Hoskins PJ, O'Reilly SE, Swenerton KD. The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int. J. Gynecol. Cancer 1, 205-208 (1991).
15. Gore ME, Fryatt I, Wiltshaw E, Dawzon T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol. Oncol. 36, 207-211 (1990).
16. Thigpen JT, Blessing JA, Ball H, Hummel SJ, Barrett RJ. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J. Clin. Oncol. 12, 1748-1753 (1994).
17. Markman M, Blessing JA, Moore D et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group Phase II trial. Gynecol. Oncol. 69, 226-229 (1998).
18. Markman M. Recurrence within 6 months of platinum-therapy: an adequate definition of 'platinum-refractory' ovarian cancer? Gynecol. Oncol. 69, 91-92 (1998).
19. Markman M, Kennedy A, Webster K et al. Evidence that a 'treatment-free interval of <6 months' does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J. Cancer Res. Clin. Oncol. 124, 326-328 (1998).
20. Rose PG, Fusco N, Fluellen L, Rodriguez M. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J. Clin. Oncol. 16, 1494-4497 (1998).
21. Stiff PJ, Bayer R, Kerger C et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J. Clin. Oncol. 15, 1309-1317 (1997).
22. Legros M, Dauplat J, Fleury J et al. High-dose chemotherapy with hematopoietic rescue in patients with Stage III to IV ovarian cancer: long-term results. J. Clin. Oncol. 15, 1302-1308 (1997).
23. Markman M. Intraperitoneal therapy of ovarian cancer. Semin. Oncol. 25, 356-360 (1998).
24. Ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15, 2183-2193 (1997).
25. Cremers GJ, Bolis G, Gore M et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J. Clin. Oncol. 14, 3056-3061 (1996).
26. Bookman MA, Malmstrom H, Bolis G et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy containing cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16, 3345-3352 (1998).
27. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15, 987-993 (1997).
28. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 16, 405-410 (1998).
29. Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 12, 60-63 (1994).
30. Vergote I, Himmelmann A, Frankendal B, Scheistroen M, Vlachos K, Trope C. Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer. Gynecol. Oncol. 47, 282-286 (1992).
31. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. Cancer Inst. 86, 1530-1533 (1994).
32. Shapiro JD, Millward MJ, Rischin D et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol. Oncol. 63, 89-93 (1996).
33. Sutton GP, Blessing JA, Homesley HD, Berman ML, Malfetano J. Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 7, 1672-1676 (1989).
34. Markman M, Hakes T, Reichman B et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum resistant disease. J. Clin. Oncol. 10, 243-248 (1991).
35. Bajetta E, Di Leo A, Biganzoli L et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 14, 2546-2551, 1996.
36. Gershenson DM, Burke TW, Morris M et al. A Phase I study of a daily x3 schedule of iv. vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol. 70, 404-409 (1998).
37. Piccart MJ, Gore M, ten Bokkel Huinink W et al. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. J. Natl Cancer Inst. 87, 676-681 (1995).
38. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68, 269-271 (1991).
39. Markman M, Iseminger KA, Hatch KD et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol. Oncol. 62, 4-6 (1996).
40. Ahlgren JD, Ellison NM, Gottlieb RJ et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive Phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol. 11, 1957-1968 (1993).
41. Markman M, Hall J, Spitz, D et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J. Clin. Oncol. 20(9), 2365-2369 (2002).
42. Rubin SC, Hoskins WJ, Hakes TB et al. Serum CA-125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am. J. Obstet. Gynecol. 160, 667-671 (1989).